Alphamab Oncology (HKG:9966) said it carried out Phase III clinical trials of its cancer drug KN046 and will publish results at industry conferences after sufficient data analysis, according to a Friday filing on the Hong Kong bourse.
The overall survival analysis showed that KN046, in combination with platinum-based chemotherapy, demonstrated statistically significant overall survival improvement compared with placebo in combination with platinum-based chemotherapy in patients with squamous non-small cell lung cancer.
The drugmaker added that there are no guarantees that the new drug application of KN046 will be accepted and approved by the regulatory authorities.
KN046 is a cancer treatment drug targeting the PD-L1/CTLA-4 bispecific antibody to improve localization with the tumor microenvironment and reduce off-target toxicity.
Price (HKD): $2.29, Change: $+0.010, Percent Change: +0.44%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。